These Stocks have Potential to gain 40% The fir
Post# of 24964
(Total Views: 167)
Posted On: 12/17/2022 7:36:24 AM
These Stocks have Potential to gain 40%
The first 6 months in the market has been a nose dive towards bearish territory, but it’s seem to taken a U-turn in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier.
The million dollar question in many investor’s mind is, is this turnaround real or just a temporary relief before the dive resumes. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - finding them will be the key to success.
>>Allogene Therapeutics, Inc. (ALLO)<<
The first stock, Allogene Therapeutics, is a biopharmaceutical company pursuing research in cancer immunotherapies, using allogenic chimeric antigen receptor T-cells, or AlloCAR T, to develop new agents for disease treatment. These are purpose-designed precision medicines that work with the patient’s own immune system to attack cancers. The company is at the clinical stage, with several drug candidates undergoing human clinical trials.
In recent news on the clinical front, Allogene’s most advanced candidate, ALLO-501A, received regenerative medicine advanced therapy (RMAT) designation from the FDA, giving the program an expedited status. ALLO-501A’s new designation followed on a positive data release from the ALPHA2 trial, which is testing the drug on patients with relapsed or refractory Large B cell Lymphoma (LBCL). The data showed that AlloCAR T therapies are safe and effective, and produce durable patient responses. The company plans to initiate a Phase 2 pivotal trial this year.
>>>Prometheus Biosciences (RXDX)<<<
The next Goldman pick we’re looking at is another biopharma in the precision medicine niche. Prometheus is working on new treatments for immune-related gastrointestinal conditions, with a focus on inflammatory bowel diseases (IBD). Most of Prometheus’ program is in early, preclinical stages, but the company does have one drug candidate, PRA023, currently undergoing three human clinical trials to treat Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). The company uses a biomarker-targeted therapeutic approach, based upon a patient’s biomarker profile. This patient-centric mode offers the promise of transformed patient outcomes.
Prometheus has recently reported several updates to its clinical trial programs of PRA023. First, the company has initiated a third Phase 2 study of the drug candidate, focusing on SSc-ILD. The study was initiated in March of this year, and top line results are expected in 1H24.
>>>Regencell Bioscience (RGC)<<<
An under the radar counter which has a possibility of moonshot is Regencell Bioscience Holding. Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
From the latest findings, Regencell Bioscience’s (TCM) treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://finance.yahoo.com/news/buy-2-stocks-jump-40-090447531.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
The first 6 months in the market has been a nose dive towards bearish territory, but it’s seem to taken a U-turn in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier.
The million dollar question in many investor’s mind is, is this turnaround real or just a temporary relief before the dive resumes. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - finding them will be the key to success.
>>Allogene Therapeutics, Inc. (ALLO)<<
The first stock, Allogene Therapeutics, is a biopharmaceutical company pursuing research in cancer immunotherapies, using allogenic chimeric antigen receptor T-cells, or AlloCAR T, to develop new agents for disease treatment. These are purpose-designed precision medicines that work with the patient’s own immune system to attack cancers. The company is at the clinical stage, with several drug candidates undergoing human clinical trials.
In recent news on the clinical front, Allogene’s most advanced candidate, ALLO-501A, received regenerative medicine advanced therapy (RMAT) designation from the FDA, giving the program an expedited status. ALLO-501A’s new designation followed on a positive data release from the ALPHA2 trial, which is testing the drug on patients with relapsed or refractory Large B cell Lymphoma (LBCL). The data showed that AlloCAR T therapies are safe and effective, and produce durable patient responses. The company plans to initiate a Phase 2 pivotal trial this year.
>>>Prometheus Biosciences (RXDX)<<<
The next Goldman pick we’re looking at is another biopharma in the precision medicine niche. Prometheus is working on new treatments for immune-related gastrointestinal conditions, with a focus on inflammatory bowel diseases (IBD). Most of Prometheus’ program is in early, preclinical stages, but the company does have one drug candidate, PRA023, currently undergoing three human clinical trials to treat Ulcerative Colitis, Crohn’s Disease, and Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD). The company uses a biomarker-targeted therapeutic approach, based upon a patient’s biomarker profile. This patient-centric mode offers the promise of transformed patient outcomes.
Prometheus has recently reported several updates to its clinical trial programs of PRA023. First, the company has initiated a third Phase 2 study of the drug candidate, focusing on SSc-ILD. The study was initiated in March of this year, and top line results are expected in 1H24.
>>>Regencell Bioscience (RGC)<<<
An under the radar counter which has a possibility of moonshot is Regencell Bioscience Holding. Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
From the latest findings, Regencell Bioscience’s (TCM) treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://finance.yahoo.com/news/buy-2-stocks-jump-40-090447531.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
(0)
(0)Scroll down for more posts ▼